The Diabetic Neuropathies
- 1 November 2004
- journal article
- research article
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 10 (6) , 311-322
- https://doi.org/10.1097/01.nrl.0000144733.61110.25
Abstract
Background: Diabetes remains the most common cause of neuropathy in the United States and is a significant source of morbidity and mortality, accounting for substantial suffering and billions of dollars in health care expenditures each year. Review Summary: Our insight into the pathophysiology of the diabetic neuropathies has increased considerably over the last decade, aided by advances in the basic science of diabetes itself. A wide variety of potential mechanisms for nerve injury in diabetes has been identified, including the polyol pathway of glucose metabolism, oxidative nerve injury, the deposition of advanced glycosylation end products within the nerve and the effects of vascular insufficiency, among others. Diabetic neuropathy may take variety of clinical forms beyond the well-know distal symmetric neuropathy, many of which are often misdiagnosed or overlooked entirely, sometimes with serious consequences for the patient. Proper therapy after diagnosis is also critical and may include not only primary management, but also treatment of painful diabetic neuropathy through an expanding repertoire of increasingly effective pharmacologic agents. Though primary treatment trials have not yet provided effective therapies, ongoing and future trials offer continuing promise. Conclusions: The diabetic neuropathies are exceedingly common, but often improperly diagnosed and incompletely treated. A proper understanding of the mechanisms underlying these diseases and the clinical recognition of their various forms is highly important as appropriate primary and symptomatic management can substantially reduce the morbidity and mortality. associated with these disorders.Keywords
This publication has 65 references indexed in Scilit:
- Economic Costs of Diabetes in the U.S. in 2002Diabetes Care, 2003
- Polyol pathway and diabetic peripheral neuropathyPublished by Elsevier ,2002
- Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitorBrain, 2001
- Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathyDiabetologia, 2001
- Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of ratNeuroscience Letters, 2001
- Diabetes trends in the U.S.: 1990-1998.Diabetes Care, 2000
- The Effect of Intensive Diabetes Therapy on the Development and Progression of NeuropathyAnnals of Internal Medicine, 1995
- Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogsDiabetologia, 1994
- The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohortNeurology, 1993
- Copper, Zinc, Manganese, and Magnesium Status and Complications of Diabetes MellitusDiabetes Care, 1991